Under Project Impact, one of four programs backed by $200 million in funds, researchers aim to harmonize EHR data and build an AI model to improve cancer care.

The firm will evaluate the drug's safety and early efficacy in patients with advanced AKT1 E17K-mutant solid tumors.

The firm will continue developing Lava's two partnered bispecific gamma delta T-cell engager programs with Pfizer and Johnson & Johnson.

BioCardia wants to gauge whether it has enough evidence to pursue regulatory approval for CardiAMP in ischemic heart failure.

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

Experts don't back specific tests, but provide guidelines on how doctors in specialty care settings can use them to diagnose ...

Neurologists from multiple clinics shared data at AAIC on the Alzheimer's drug's use, shedding light on its safety and ...

The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...

Despite regulatory setbacks, the petitioners believe that survival and other data they've collected themselves are worth ...

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

In a new paper, a team from Yale and Fred Hutch has found autoantibody reactivity could predict cancer patients' response to ...

As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline ...